Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. CRISPR Therapeutics AG shares valued at $50,399 were sold by KASINGER JAMES R. on Oct 14 ’24. At $46.28 per share, KASINGER JAMES R. sold 1,089 shares. The insider’s holdings dropped to 62,597 shares worth approximately $3.07 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Kulkarni Samarth sold 4,293 shares, netting a total of over 198,680 in proceeds. Following the sale of shares at $46.28 each, the insider now holds 226,540 shares.
Before that, Bruno Julianne had sold 3,366 shares from its account. In a trade valued at $188,799, the Chief Operating Officer traded CRISPR Therapeutics AG shares for $56.09 each. Upon closing the transaction, the insider’s holdings decreased to 3,366 shares, worth approximately $0.33 million.
As published in a research note from Needham on August 06, 2024, CRISPR Therapeutics AG [CRSP] has been retained to a Buy and the price target has been revised to $84. Analysts at Rodman & Renshaw started covering the stock with ‘”a Buy”‘ outlook in a report released in early August. Earlier on February 15, 2024, Wolfe Research initiated its rating. Their recommendation was “a Peer perform” for CRSP stock.
Analyzing CRSP Stock Performance
During the last five days, there has been a surge of approximately 7.93%. Over the course of the year, CRISPR Therapeutics AG shares have dropped approximately -21.73%. Shares of the company reached a 52-week high of $91.10 on 02/22/24 and a 52-week low of $43.42 on 09/06/24. A 50-day SMA is recorded $47.13, while a 200-day SMA reached $59.07. Nevertheless, trading volume fell to 1.0 million shares from 0.87 million shares the previous day.
Support And Resistance Levels for CRISPR Therapeutics AG (CRSP)
According to the 24-hour chart, there is a support level at 48.18, which, if violated, would cause prices to drop to 47.37. In the upper region, resistance lies at 49.53. The next price resistance is at 50.07. RSI (Relative Strength Index) is 60.55 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 1.93, which suggests the price will increase in the coming days. Percent R is at 5.20%, indicating bullish price movement. Stochastics %K at selling indicates that the stock is to be held.
